浅述睑板腺功能障碍(MGD)的治疗进展
|
摘要
睑板腺功能障碍是指患者睑板腺出现弥漫性病变,睑板腺导管发生阻塞,并且睑酯分泌质量发生异常,从而导致泪膜异常,出现眼部炎症反应和刺激症状[1]。MGD最初临床表现主要是患者睑板腺体开口出现隆起,随着疾病进展,临床表现出现睑缘、睑板腺开口、腺泡异常变化和黏膜皮肤交界线以及主导管,进而导致泪膜的不稳定、蒸发性干眼和睑板腺分泌脂质的形态发生改变等,疾病严重患者者可导致出现结膜和角膜发生改变[2]。其临床表现主要为睑板腺炎、睑板腺分泌异常以及睑板腺管阻塞等症状。干眼降低患者的生活质量,MGD被认为是蒸发过强型干眼的主要原因之一。但是在临床上关于MGD的发病机制尚不明确[3]。目前在临床上用于MGD治疗方法较多,本文对MGD的各种治疗方法做一综述。
The meibomian gland dysfunction refers to the meibomian gland in patients with diffuse lesions, meibomian gland duct obstruction, and eyelid ester production quality an exception occurs, resulting in abnormal appears,ocular inflammation and stimulating symptoms[1].MDGS initial clinical manifestations mainly uplift, meibomian gland openings to occur in patients with disease progression, the clinical manifestations of eyelid margin,meibomian gland openings, abnormal changes skin and mucosa gland bubble boundary and led tube, thus leading to the instability of film ACTS, evaporative dry eye and lipid meibomian gland secretion form change, etc., in patients with severe disease could lead to change of conjunctiva and corneal[2].The main clinical manifestations of the disease were blepharitis, abnormal secretion of the meibomian gland and obstruction of the meibomian duct. Dry eyes reduce the quality of life of patients, and MGD was considered to be one of the main causes of evaporative hyperstrength dry eyes.However, the pathogenesis of MGD was not clear in clinical practice[3].At present, MGD was widely used in clinical treatment methods. This paper summarized various treatment methods of MGD.
The meibomian gland dysfunction refers to the meibomian gland in patients with diffuse lesions, meibomian gland duct obstruction, and eyelid ester production quality an exception occurs, resulting in abnormal appears,ocular inflammation and stimulating symptoms[1].MDGS initial clinical manifestations mainly uplift, meibomian gland openings to occur in patients with disease progression, the clinical manifestations of eyelid margin,meibomian gland openings, abnormal changes skin and mucosa gland bubble boundary and led tube, thus leading to the instability of film ACTS, evaporative dry eye and lipid meibomian gland secretion form change, etc., in patients with severe disease could lead to change of conjunctiva and corneal[2].The main clinical manifestations of the disease were blepharitis, abnormal secretion of the meibomian gland and obstruction of the meibomian duct. Dry eyes reduce the quality of life of patients, and MGD was considered to be one of the main causes of evaporative hyperstrength dry eyes.However, the pathogenesis of MGD was not clear in clinical practice[3].At present, MGD was widely used in clinical treatment methods. This paper summarized various treatment methods of MGD.
引文
[1]杨帆,曾庆延.睑板腺功能障碍治疗进展[J].眼科新进展,2016,36(10):996-1000.
[2]于春红,王云松.睑板腺功能障碍的治疗及研究进展[J].海南医学,2018(4):531-534.
[3]张明明,庄曾渊,胡怀彬,等.睑板腺功能障碍的病因病机及中医治疗研究进展[J].中国中医眼科杂志,2017, 27(2):134-136.
[4]徐凤,王梅艳,李之忠,等.睑板腺管按摩联合药物治疗睑板腺功能障碍的临床疗效[J].国际眼科杂志,2017,17(11):2164-2166.
[5]高英,刘莹,符碧峰.睑板腺功能障碍的研究进展[J].中国中医眼科杂志,2016,26(3):201-205.
[6]丁剑锋,罗远湘,李璐.妥布霉素地塞米松治疗睑板腺功能障碍的临床观察[J].中国药房,2017, 28(15):2060-2062.
[7]陈旭,马华峰.睑板腺功能障碍临床诊断新进展[J].国际眼科杂志,2018,18(6):1051-1054.
[8]刘慧峰,王霞,韩双羽,等.物理疗法联合妥布霉素地塞米松眼膏治疗睑板腺功能障碍临床观察[J].陕西医学杂志,2017,46(10):1436-1437.
[9]刘锦魁,唐健青.重组牛碱性成纤维细胞生长因子眼用凝胶在睑板腺异常相关干眼患者中的临床应用[J].海南医学,2017,28(4):658-659.
[10]余婷.睑板腺功能障碍的治疗及其进展[J].中华实验眼科杂志,2018,36(2):150-155.
[11]吴梦亮,王艳.睑缘炎治疗进展[J].中国眼耳鼻喉科杂志,2017,17(3):208-212.
[12]牟洁,白宁艳,刘雪莲,等.睑板腺功能障碍性干眼症治疗研究[J].世界最新医学信息文摘,2017,17(44):58-59.
[13]刘泽源,李才锐.睑板腺功能障碍所致干眼的治疗[J].国际眼科杂志,2014,14(2):270-272.
[14]谭业双,周霞,许玲,等.抗炎治疗睑板腺功能障碍的临床研究[J].眼科新进展,2012,32(1):81-83.
[15]刘李平,冀垒兵,高晓唯,等.综合治疗睑板腺功能障碍性干眼的疗效观察[J].国际眼科杂志,2014,14(12):2292-2294.
[16]徐凤,王梅艳,李之忠,等.睑板腺管按摩联合药物治疗睑板腺功能障碍的临床疗效[J].国际眼科杂志,2017,17(11):2164-2166.
[17]矫红,武燕,杨亚丽,等.养阴清热、健脾化痰法治疗睑板腺功能障碍及其相关干眼的临床观察[J].现代中医临床,2016,23(1):38-43.
[18]郭彦,霍妍佼.睑板腺功能障碍治疗与护理的研究进展[J].中华现代护理杂志,2015,21(28):3467-3469.
[2]于春红,王云松.睑板腺功能障碍的治疗及研究进展[J].海南医学,2018(4):531-534.
[3]张明明,庄曾渊,胡怀彬,等.睑板腺功能障碍的病因病机及中医治疗研究进展[J].中国中医眼科杂志,2017, 27(2):134-136.
[4]徐凤,王梅艳,李之忠,等.睑板腺管按摩联合药物治疗睑板腺功能障碍的临床疗效[J].国际眼科杂志,2017,17(11):2164-2166.
[5]高英,刘莹,符碧峰.睑板腺功能障碍的研究进展[J].中国中医眼科杂志,2016,26(3):201-205.
[6]丁剑锋,罗远湘,李璐.妥布霉素地塞米松治疗睑板腺功能障碍的临床观察[J].中国药房,2017, 28(15):2060-2062.
[7]陈旭,马华峰.睑板腺功能障碍临床诊断新进展[J].国际眼科杂志,2018,18(6):1051-1054.
[8]刘慧峰,王霞,韩双羽,等.物理疗法联合妥布霉素地塞米松眼膏治疗睑板腺功能障碍临床观察[J].陕西医学杂志,2017,46(10):1436-1437.
[9]刘锦魁,唐健青.重组牛碱性成纤维细胞生长因子眼用凝胶在睑板腺异常相关干眼患者中的临床应用[J].海南医学,2017,28(4):658-659.
[10]余婷.睑板腺功能障碍的治疗及其进展[J].中华实验眼科杂志,2018,36(2):150-155.
[11]吴梦亮,王艳.睑缘炎治疗进展[J].中国眼耳鼻喉科杂志,2017,17(3):208-212.
[12]牟洁,白宁艳,刘雪莲,等.睑板腺功能障碍性干眼症治疗研究[J].世界最新医学信息文摘,2017,17(44):58-59.
[13]刘泽源,李才锐.睑板腺功能障碍所致干眼的治疗[J].国际眼科杂志,2014,14(2):270-272.
[14]谭业双,周霞,许玲,等.抗炎治疗睑板腺功能障碍的临床研究[J].眼科新进展,2012,32(1):81-83.
[15]刘李平,冀垒兵,高晓唯,等.综合治疗睑板腺功能障碍性干眼的疗效观察[J].国际眼科杂志,2014,14(12):2292-2294.
[16]徐凤,王梅艳,李之忠,等.睑板腺管按摩联合药物治疗睑板腺功能障碍的临床疗效[J].国际眼科杂志,2017,17(11):2164-2166.
[17]矫红,武燕,杨亚丽,等.养阴清热、健脾化痰法治疗睑板腺功能障碍及其相关干眼的临床观察[J].现代中医临床,2016,23(1):38-43.
[18]郭彦,霍妍佼.睑板腺功能障碍治疗与护理的研究进展[J].中华现代护理杂志,2015,21(28):3467-3469.